| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Aspergum 227.5mg gum tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Co-codaprin 8mg/500mg dispersible tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing aspirin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Acetylsalicylic acid measurement, quantitative |
Component |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Isosorbide mononitrate+aspirin (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Isosorbide mononitrate+aspirin 60mg/150mg m/r tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Isosorbide mononitrate+aspirin 60mg/75mg m/r tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Antiplatelet aspirin |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing aspirin and dipyridamole (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Dipyridamole+aspirin 200mg/25mg m/r capsule (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely aspirin DL-lysine 900 milligram and metoclopramide hydrochloride 10 milligram/1 sachet conventional release oral powder (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely aspirin 325 milligram and butalbital 50 milligram and caffeine 40 milligram and codeine phosphate 30 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing aspirin and carisoprodol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Product containing aspirin and butalbital and caffeine and codeine phosphate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing aspirin and meprobamate (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Product containing aspirin and caffeine and propoxyphene hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing aspirin and glycine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Product containing aspirin and caffeine and dihydrocodeine tartrate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Aspirin + caffeine + orphenadrine citrate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing aspirin and hydrocodone bitartrate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing aspirin and carisoprodol and codeine phosphate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing aspirin and butalbital and caffeine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Product containing aspirin and oxycodone hydrochloride and oxycodone terephthalate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Aspirin + cyclizine hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing aspirin and metoclopramide (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Product containing aspirin and methocarbamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Aspirin + pentazocine hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing aspirin and papaveretum (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Aspirin + codeine 500mg/8mg dispersible tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Aspirin+papaveretum 500mg/10mg dispersible tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Aspirin 300 mg and codeine 8 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing aspirin and pravastatin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Aspirin 81 mg and pravastatin 20 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Aspirin 81 mg and pravastatin 40 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Aspirin 81 mg and pravastatin 80 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Aspirin 325 mg and pravastatin 80 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Aspirin 325 mg and pravastatin 40 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Aspirin 325 mg and pravastatin 20 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Aspirin- and caffeine- and cinnamedrine-containing product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Product containing aspirin and codeine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Carisoprodol + aspirin |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing aspirin and caffeine and orphenadrine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
| Aspirin + oxycodone hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing buffered aspirin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing buffered aspirin and caffeine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Aspirin- and caffeine- and paracetamol-containing product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Product containing aspirin and caffeine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Aspirin 325 mg and codeine 30 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely aspirin 325 milligram and codeine 60 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely aspirin 389 milligram and caffeine 32.4 milligram and dextropropoxyphene hydrochloride 32 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely aspirin 250 milligram and caffeine 65 milligram and paracetamol 250 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Intentional aspirin poisoning |
Causative agent (attribute) |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Aspirin-induced asthma |
Causative agent (attribute) |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Aloxiprin (substance) |
Is a |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing aspirin and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Buffered aspirin (substance) |
Is a |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Administration of aspirin |
Direct substance |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Aluminum aspirin |
Is a |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Administration of aspirin |
Direct substance |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Accidental poisoning by aspirin |
Causative agent (attribute) |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Administration of prophylactic aspirin for ischemic heart disease (procedure) |
Direct substance |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Administration of prophylactic aspirin |
Direct substance |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Aspirin exacerbated respiratory disease |
Causative agent (attribute) |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
| Allergy to aspirin |
Causative agent (attribute) |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Aspirin therapy |
Direct substance |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Aspirin 75 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Aspirin 75 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Aspirin 300 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Aspirin 300 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Aspirin 325 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Aspirin 325 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Aspirin 800 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Aspirin 800 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Aspirin 975 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Aspirin 975 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing precisely aspirin 325 milligram and butalbital 50 milligram and caffeine 40 milligram/1 each conventional release oral capsule (clinical drug) |
Has basis of strength substance (attribute) |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Aspirin 385 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
Has basis of strength substance (attribute) |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Aspirin 856 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Aspirin 856 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
Has basis of strength substance (attribute) |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Aspirin 389 mg and caffeine 32.4 mg and dextropropoxyphene hydrochloride 65 mg oral capsule |
Has basis of strength substance (attribute) |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Aspirin 500 mg and hydrocodone bitartrate 5 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Aspirin 500 mg and hydrocodone bitartrate 5 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Aspirin 325 mg and meprobamate 200 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Aspirin 325 mg and meprobamate 200 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Aspirin 325 mg and methocarbamol 400 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Aspirin 325 mg and oxycodone hydrochloride 2.25 mg and oxycodone terephthalate 190 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Aspirin 325 mg and oxycodone hydrochloride 2.25 mg and oxycodone terephthalate 190 microgram oral tablet |
Has basis of strength substance (attribute) |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Aspirin 300 mg and codeine 8 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Aspirin 81 mg and pravastatin 20 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Aspirin 81 mg and pravastatin 20 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Aspirin 81 mg and pravastatin 40 mg oral tablet |
Has basis of strength substance (attribute) |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Aspirin 81 mg and pravastatin 80 mg oral tablet |
Has basis of strength substance (attribute) |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Aspirin 325 mg and pravastatin 80 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Aspirin 325 mg and pravastatin 80 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Aspirin 325 mg and pravastatin 40 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Aspirin 325 mg and pravastatin 40 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Aspirin 325 mg and pravastatin 20 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Aspirin 325 mg and pravastatin 20 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Aspirin 325 mg and codeine 30 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing precisely aspirin 325 milligram and codeine 60 milligram/1 each conventional release oral tablet (clinical drug) |
Has basis of strength substance (attribute) |
True |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing precisely aspirin 250 milligram and caffeine 65 milligram and paracetamol 250 milligram/1 each conventional release oral tablet (clinical drug) |
Has basis of strength substance (attribute) |
False |
Aspirin (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.4-SNAPSHOT
|
FHIR Version n/a
User: [n/a]